<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="iid370203" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Immun Inflamm Dis</journal-id><journal-id journal-id-type="iso-abbrev">Immun Inflamm Dis</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2050-4527</journal-id><journal-id journal-id-type="publisher-id">IID3</journal-id><journal-title-group><journal-title>Immunity, Inflammation and Disease</journal-title></journal-title-group><issn pub-type="epub">2050-4527</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40396593</article-id><article-id pub-id-type="pmc">PMC12093350</article-id><article-id pub-id-type="doi">10.1002/iid3.70203</article-id><article-id pub-id-type="publisher-id">IID370203</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Role of P2X7R in Retinal Diseases: A Review</article-title></title-group><contrib-group><contrib id="iid370203-cr-0001" contrib-type="author"><name><surname>Li</surname><given-names>Chunli</given-names></name><xref rid="iid370203-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="iid370203-cr-0002" contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Binsheng</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1206-5843</contrib-id><xref rid="iid370203-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>ldyy_wangbs@lzu.edu.cn</email></address></contrib></contrib-group><aff id="iid370203-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Ophthalmology</named-content>
<institution>The Second Hospital of Lanzhou University</institution>
<city>Lanzhou</city>
<named-content content-type="country-part">Gansu</named-content>
<country country="CN">China</country>
</aff><aff id="iid370203-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of General Surgery</named-content>
<institution>The First Hospital of Lanzhou University</institution>
<city>Lanzhou</city>
<named-content content-type="country-part">Gansu</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Binsheng Wang (<email>ldyy_wangbs@lzu.edu.cn</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>13</volume><issue seq="20">5</issue><issue-id pub-id-type="doi">10.1002/iid3.v13.5</issue-id><elocation-id>e70203</elocation-id><history>
<date date-type="rev-recd"><day>16</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>04</day><month>1</month><year>2025</year></date>
<date date-type="accepted"><day>25</day><month>4</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Immunity, Inflammation and Disease</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:IID3-13-e70203.pdf"/><abstract><title>ABSTRACT</title><sec id="iid370203-sec-0010"><title>Background</title><p>P2X purinoceptor 7 receptor (P2X7R) is an ATP&#x02010;gated ion channel that, upon activation by ATP, triggers the release of inflammatory mediators and induces apoptosis in cells. This channel plays a crucial role in the onset and progression of various diseases. Recently, there has been a growing body of research focused on the function of P2X7R receptors in ophthalmic conditions, particularly concerning retinal diseases such as age&#x02010;related macular degeneration, diabetic retinopathy, and retinitis pigmentosa.</p></sec><sec id="iid370203-sec-0020"><title>Objective</title><p>This article is to provide a comprehensive review of the advancements in the study of P2X7R and its association with retinal diseases, elucidating its role in these conditions and identifying potential avenues for future research.</p></sec><sec id="iid370203-sec-0030"><title>Methods</title><p>Electronic databases, including PubMed, Web of Science, and Wan fang Data were searched for relevant literature. The following keywords were used: &#x0201c;P2X7R&#x0201d;, Age&#x02010;related macular degeneration&#x0201d;, &#x0201c;Diabetic retinopathy&#x0201d;, &#x0201c;Retinitis pigmentosa&#x0201d;. Both preclinical and clinical studies were included to provide a holistic understanding of P2X7R's role in retinal pathology.</p></sec><sec id="iid370203-sec-0040"><title>Results</title><p>P2X7R activation exacerbates retinal diseases by promoting inflammation and apoptosis. However, its role in disease progression and homeostasis complicates therapeutic targeting, highlighting the need for selective inhibitors and further research into its context&#x02010;dependent functions.</p></sec><sec id="iid370203-sec-0050"><title>Conclusion</title><p>P2X7R plays a critical role in the pathogenesis of retinal diseases. At the same time, preclinical studies suggest that P2X7R inhibition holds promise as a therapeutic strategy. Future research should focus on developing selective P2X7R inhibitors, elucidating the receptor's role in different disease stages, and identifying biomarkers to guide personalized treatment. Addressing these challenges will be essential for translating P2X7R&#x02010;targeted therapies into clinical practice and improving outcomes for patients with retinal diseases.</p></sec></abstract><kwd-group><kwd id="iid370203-kwd-0001">age&#x02010;related macular degeneration</kwd><kwd id="iid370203-kwd-0002">diabetic retinopathy</kwd><kwd id="iid370203-kwd-0003">P2X7R</kwd><kwd id="iid370203-kwd-0004">retinal</kwd><kwd id="iid370203-kwd-0005">retinitis pigmentosa</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>This study was supported by the Natural Science Foundation of Gansu Province (22JR5RA971).
</institution><institution-id institution-id-type="doi">10.13039/501100004775</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="10"/><word-count count="6993"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="iid370203-sec-0060"><label>1</label><title>Introduction</title><p>With the ongoing advancements in biomedical technology, research on retinal diseases has become increasingly comprehensive. P2X7R, an ion channel protein that is widely distributed across cell membranes, has garnered significant attention in the field of retinal disease research in recent years [<xref rid="iid370203-bib-0001" ref-type="bibr">1</xref>, <xref rid="iid370203-bib-0002" ref-type="bibr">2</xref>, <xref rid="iid370203-bib-0003" ref-type="bibr">3</xref>]. The distinctive structure of P2X7R is pivotal in processes such as signal transduction, cell apoptosis, and inflammatory responses, all of which are closely linked to the pathogenesis of retinal diseases. Therefore, a review of the research progress regarding P2X7R and retinal&#x02010;related diseases will deepen our understanding of the underlying mechanisms and offer novel insights and strategies for clinical treatment.</p><p>P2X7R is a nonselective cation channel protein that belongs to the P2X subfamily. It is predominantly expressed on cell membranes and is involved in the exchange and signal transduction of ions both intracellularly and extracellularly [<xref rid="iid370203-bib-0004" ref-type="bibr">4</xref>]. In the retina, P2X7R is widely distributed among neurons and glial cells in both the inner and outer synapse&#x02010;rich layers, as well as in the nuclear layers of the retina [<xref rid="iid370203-bib-0005" ref-type="bibr">5</xref>], playing a crucial role in regulating neurotransmitter release and neuronal excitability. In terms of ATP signaling, ATP in the retina activates P2X7R, modulating calcium ion (Ca&#x000b2;&#x0207a;) influx, which influences neuronal activity and signal transmission. Additionally, P2X7R may be involved in the regulation of synaptic plasticity in the retina, thereby affecting the processing of visual information [<xref rid="iid370203-bib-0005" ref-type="bibr">5</xref>, <xref rid="iid370203-bib-0006" ref-type="bibr">6</xref>]. As research on P2X7R advances, numerous studies have increasingly demonstrated a significant correlation between P2X7R and the onset and progression of various retinal diseases. For instance, in age&#x02010;related macular degeneration, elevated expression levels of P2X7R may contribute to the apoptosis and dysfunction of retinal cells [<xref rid="iid370203-bib-0007" ref-type="bibr">7</xref>]. In the context of diabetic retinopathy, abnormal expression of P2X7R could exacerbate inflammatory responses and further compromise retinal cell integrity. Furthermore, P2X7R is also implicated in the pathogenesis of retinal pigmentary degeneration and optic neuritis [<xref rid="iid370203-bib-0008" ref-type="bibr">8</xref>].</p><p>In this paper, we systematically summarize the role of P2X7R in retinal diseases, including age&#x02010;related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP). Our objective is to highlight its involvement in inflammatory processes, apoptosis, ion channel signaling, and retinal degeneration. Additionally, we will discuss the potential of P2X7R as a therapeutic target and evaluate the challenges associated with translating preclinical findings into clinical applications. By identifying gaps and controversies in current research, this review seeks to provide valuable insights for future studies and therapeutic development.</p></sec><sec id="iid370203-sec-0070"><label>2</label><title>Literature Search</title><p>We conducted a literature search in PubMed, Web of Science, and Wan fang Data using keywords &#x0201c;P2X7R&#x0201d;, &#x0201c;Age&#x02010;related macular degeneration&#x0201d;, &#x0201c;Diabetic retinopathy&#x0201d;, and &#x0201c;Retinitis pigmentosa&#x0201d;. The initial screening process involved excluding irrelevant studies by reviewing titles and abstracts. This was followed by a full&#x02010;text review for further refinement, ultimately including only those studies that met the established criteria. We then categorized the literature according to the role of P2X7R in retinal diseases and extracted key data. In the presentation of results section, we summarized the mechanisms of P2X7R in various diseases using tables. Additionally, we provided a narrative synthesis organized thematically within the manuscript.</p></sec><sec id="iid370203-sec-0080"><label>3</label><title>P2X7R</title><p>The P2X receptor family comprises seven subtypes (P2X1 to P2X7R), each characterized by a unique transmembrane structure that allows for the rapid transduction of extracellular ATP signals into intracellular responses [<xref rid="iid370203-bib-0009" ref-type="bibr">9</xref>]. Short&#x02010;term activation of the P2X7 receptor by ATP (&#x02009;&#x0003c;&#x02009;10&#x02009;s) leads to rapid and reversible channel openings, permitting the passage of Na&#x0207a;, K&#x0207a;, and Ca&#x000b2;&#x0207a; ions. Under normal physiological conditions, the presence of P2X7 receptors contributes to cell survival, regulates immune cell activity, and modulates inflammatory responses. However, in hypoxic or ischemic environments, elevated ATP concentrations, bacterial products, and inflammatory mediators increase the number of P2X7 receptors and heighten their sensitivity to ATP. Prolonged stimulation of these receptors results in the formation of large pores in the plasma membrane, allowing the uptake of cationic molecules up to 900&#x02009;Da. This process further promotes the release of inflammatory mediators and ultimately leads to cell death [<xref rid="iid370203-bib-0010" ref-type="bibr">10</xref>]. Among these, P2X7R has garnered significant attention due to its high expression levels in immune cells and its pivotal role in activation, inflammatory responses, and apoptosis [<xref rid="iid370203-bib-0011" ref-type="bibr">11</xref>]. Furthermore, P2X7R has been implicated in the pathogenesis of various diseases, including autoimmune disorders, neurodegenerative diseases, and certain cancers [<xref rid="iid370203-bib-0012" ref-type="bibr">12</xref>, <xref rid="iid370203-bib-0013" ref-type="bibr">13</xref>, <xref rid="iid370203-bib-0014" ref-type="bibr">14</xref>, <xref rid="iid370203-bib-0015" ref-type="bibr">15</xref>].</p><p>The P2X7R receptor is a trimeric protein characterized by an amino terminal, an extracellular domain, and a carboxy terminal. Each of these components contains two membrane&#x02010;spanning helices and a substantial extracellular domain that serves as the ATP binding site [<xref rid="iid370203-bib-0004" ref-type="bibr">4</xref>]. Upon ATP binding, the receptor undergoes conformational alterations that result in the opening of an ion channel. This process allows the influx of cations, such as Ca&#x000b2;&#x0207a; and Na&#x0207a;, into the cell while simultaneously facilitating the efflux of K&#x0207a; [<xref rid="iid370203-bib-0016" ref-type="bibr">16</xref>, <xref rid="iid370203-bib-0017" ref-type="bibr">17</xref>]. This ion flux is essential for the initiating intracellular signaling cascades, which include the activation of various kinases and the release of pro&#x02010;inflammatory cytokines.</p><p>P2X7R is predominantly expressed in various immune cell types, including monocytes, macrophages, and T cells, plays a crucial role in mediating immune responses [<xref rid="iid370203-bib-0004" ref-type="bibr">4</xref>, <xref rid="iid370203-bib-0018" ref-type="bibr">18</xref>]. Specifically, P2X7R is implicated in the formation of the NLRP3 inflammasome, which is essential for the production of pro&#x02010;inflammatory cytokines such as IL&#x02010;1&#x003b2; and IL&#x02010;18 [<xref rid="iid370203-bib-0019" ref-type="bibr">19</xref>, <xref rid="iid370203-bib-0020" ref-type="bibr">20</xref>, <xref rid="iid370203-bib-0021" ref-type="bibr">21</xref>]. This pathway is particularly significant in the context of chronic inflammation and autoimmune disorders. Recent studies indicate that P2X7R is vital for maintaining the homeostasis of the retinal microenvironment [<xref rid="iid370203-bib-0002" ref-type="bibr">2</xref>, <xref rid="iid370203-bib-0022" ref-type="bibr">22</xref>, <xref rid="iid370203-bib-0023" ref-type="bibr">23</xref>]. As a cation channel, P2X7R facilitates intercellular communication among retinal cells, which is essential for visual signal processing and the overall health of the retina. Furthermore, the modulation of ion flow through P2X7R is critical for preserving the stability of the retinal environment and supporting normal physiological functions [<xref rid="iid370203-bib-0024" ref-type="bibr">24</xref>].</p><p>Following retinal injury, activated immune cells, including macrophages and microglia, secrete a variety of bioactive molecules, such as ATP, which interact with P2X7R receptors. This interaction facilitates an increased flow of ions, initiating a cascade of inflammatory responses that may either support tissue repair or, conversely, contribute to retinal degeneration. The dual functionality of P2X7R highlights its potential as a therapeutic target; while it can mediate protective mechanisms in the aftermath of injury, excessive or dysregulated activation of P2X7R may lead to detrimental outcomes, including chronic inflammation and neuronal cell death.</p></sec><sec id="iid370203-sec-0090"><label>4</label><title>P2X7R and Retinal Diseases</title><sec id="iid370203-sec-0100"><label>4.1</label><title>Diabetic Retinopathy</title><p>Diabetic retinopathy is a common ocular complication among individuals with diabetes, characterized by alterations in both the structure and function of the retina. As diabetes progresses, the deterioration of retinal integrity can lead to a significant decline in visual acuity and, in severe cases, result in blindness [<xref rid="iid370203-bib-0025" ref-type="bibr">25</xref>]. Studies suggest that elevated expression levels of P2X7R are observed in diabetic patients, which may be associated with the inflammatory response and immune responses triggered by diabetes [<xref rid="iid370203-bib-0026" ref-type="bibr">26</xref>, <xref rid="iid370203-bib-0027" ref-type="bibr">27</xref>]. Additionally, P2X7R plays a critical role in the apoptotic processes of retinal neurons, thereby contributing to the onset and progression of neurodegenerative diseases. P2X7R is associated with retinal vasculopathy, which may precipitate vascular inflammatory responses and subsequent vascular damage [<xref rid="iid370203-bib-0028" ref-type="bibr">28</xref>]. Diabetes increased the vulnerability of retinal microvessels to sustained P2X7R activation, leading to the formation of large transmembrane pores and increased apoptosis and cell death [<xref rid="iid370203-bib-0029" ref-type="bibr">29</xref>]. Research has shown that the CD40&#x02010;ATP&#x02010;P2X7R pathway not only exacerbates inflammation but also induces retinal endothelial cell death, a key event in the development of capillary degeneration and retinal ischemia [<xref rid="iid370203-bib-0030" ref-type="bibr">30</xref>, <xref rid="iid370203-bib-0031" ref-type="bibr">31</xref>]. Hyperglycemia triggers increased expression and opening of connexin 43 hemichannels on the cell membrane, resulting in elevated extracellular ATP levels. Subsequently, the increased extracellular ATP binds to P2X7R and directly activates the NLRP3 inflammasome, thereby initiating pyroptosis in HRMECs [<xref rid="iid370203-bib-0032" ref-type="bibr">32</xref>, <xref rid="iid370203-bib-0033" ref-type="bibr">33</xref>].</p><p>The activation of the P2X7R receptor may exacerbate the inflammatory response associated with diabetic retinopathy [<xref rid="iid370203-bib-0030" ref-type="bibr">30</xref>]. Activated macrophages and immune cells release a variety of bioactive molecules, including proteins associated with the P2X7R channel [<xref rid="iid370203-bib-0002" ref-type="bibr">2</xref>, <xref rid="iid370203-bib-0034" ref-type="bibr">34</xref>]. Following P2X7R activation, there is an enhancement in the release of inflammatory mediators, such as the cytokines IL&#x02010;1&#x003b2;, IL&#x02010;6, and TNF&#x02010;&#x003b1; [<xref rid="iid370203-bib-0019" ref-type="bibr">19</xref>]. Furthermore, P2X7R activation enhances the expression of adhesion molecules, such as intercellular adhesion molecule&#x02010;1 (ICAM&#x02010;1) [<xref rid="iid370203-bib-0035" ref-type="bibr">35</xref>], which facilitates the adhesion and infiltration of inflammatory cells [<xref rid="iid370203-bib-0036" ref-type="bibr">36</xref>]. These bioactive substances interact with P2X7R receptors to promote intracellular ion flow, thereby contributing to the inflammatory response. Research indicates that abnormal expression of P2X7R may lead to the apoptosis of retinal neurons and the exacerbation of neurodegenerative diseases, potentially linked to P2X7R&#x02010;mediated Ca<sup>2+</sup> influx and neuronal death pathways [<xref rid="iid370203-bib-0037" ref-type="bibr">37</xref>]. Additionally, P2X7R may be implicated in the vascular damage observed in DR, including the production of nitric oxide (NO) and reactive oxygen species (ROS) [<xref rid="iid370203-bib-0038" ref-type="bibr">38</xref>]. The activation of P2X7R may further promote vascular inflammatory reactions.</p><p>Molecules associated with vascular endothelial cell injury, such as Vascular Endothelial Growth Factor (VEGF) [<xref rid="iid370203-bib-0028" ref-type="bibr">28</xref>], suggest that the P2X7R receptor may influence the growth and repair mechanisms of vascular endothelial cells. Inhibition of P2X7R may mitigate blood&#x02010;retinal barrier (BRB) dysfunction induced by hyperglycemic conditions [<xref rid="iid370203-bib-0039" ref-type="bibr">39</xref>, <xref rid="iid370203-bib-0040" ref-type="bibr">40</xref>]. The retinal vasculature in diabetic patients frequently experiences complications such as narrowing, occlusion, and leakage, which can lead to retinal ischemia and hypoxia, thereby exacerbating retinal damage [<xref rid="iid370203-bib-0027" ref-type="bibr">27</xref>]. Aberrant expression of P2X7R may amplify the extent of vascular inflammation and injury. The P2X7R receptor is integral to the progression of diabetic retinopathy. By modulating the expression and functionality of P2X7R, it may be possible to protect the retina from damage, decelerate the advancement of neurodegenerative diseases, and enhance vascular function.</p><p>Although numerous studies have demonstrated that P2X7 receptor inhibitors can delay the progression of diabetic retinopathy, some research indicates that P2X7R may play a beneficial role in clearing pathogen infections during infectious diseases [<xref rid="iid370203-bib-0041" ref-type="bibr">41</xref>, <xref rid="iid370203-bib-0042" ref-type="bibr">42</xref>]. This presents certain challenges. In the future, it may be essential to further investigate the role of P2X7R at various stages of diseases and develop biomarkers based on P2X7R expression or activity to guide personalized treatment. The function of P2X7R may differ across various diseases (or even at different stages of the same disease), highlighting the need for the development of disease&#x02010;specific intervention strategies.</p></sec><sec id="iid370203-sec-0110"><label>4.2</label><title>Age&#x02010;Related Macular Degeneration</title><p>Age&#x02010;related Macular Degeneration (AMD) is a common retinal condition associated with the aging process. It is characterized by the deterioration of central vision, alterations in the retinal pigment epithelium, and the formation of abnormal subretinal deposits [<xref rid="iid370203-bib-0043" ref-type="bibr">43</xref>, <xref rid="iid370203-bib-0044" ref-type="bibr">44</xref>]. These pathologies symptoms such as blurred vision and distortion of straight lines, which may ultimately result in progressive vision loss and potential blindness [<xref rid="iid370203-bib-0045" ref-type="bibr">45</xref>]. At the molecular biological level, the progression of AMD is closely associated with the expression and function of the P2X7R [<xref rid="iid370203-bib-0022" ref-type="bibr">22</xref>, <xref rid="iid370203-bib-0046" ref-type="bibr">46</xref>]. P2X7R is a nonselective cation channel that plays a critical role in retinal cellular function. Research has indicated that upon activation, P2X7R can further stimulate the NLRP3/Caspase&#x02010;1 signaling pathway, resulting in the release of numerous inflammatory factors that may exacerbate the progression of AMD. Furthermore, this activation can lead to an increase in VEGF levels [<xref rid="iid370203-bib-0047" ref-type="bibr">47</xref>]. A study has demonstrated that P2X7R is instrumental in facilitating paracrine communication between retinal cells and microglia, which are likely the first cells to detect ATP expression induced by retinal injury. This process involves the communication between different retinal cell types and ultimately contributes to the progression of AMD [<xref rid="iid370203-bib-0048" ref-type="bibr">48</xref>]. In a mouse model of light&#x02010;induced retinal degeneration, it has been shown that P2X7R is overexpressed in damaged retinal tissue, and downregulating P2X7R protein levels can prevent the loss of retinal photoreceptors and cell apoptosis [<xref rid="iid370203-bib-0022" ref-type="bibr">22</xref>].</p><p>Interestingly, studies have demonstrated that, compared to wild&#x02010;type mice, P2X7 KO mice exhibit diminished phagocytic function in monocytes and macrophages, as well as phenotypic characteristics reminiscent of the early stages of AMD. These characteristics include thickening of Bruch's membrane, loss of retinal pigment epithelial cells, and subretinal inflammation [<xref rid="iid370203-bib-0049" ref-type="bibr">49</xref>]. Subsequent research has revealed a novel biological function of the P2X7R: the regulation of membrane fluidity in leukocytes. This function operates independently of its roles in mediating phagocytosis and pore formation, presenting a promising therapeutic target for late&#x02010;stage AMD [<xref rid="iid370203-bib-0050" ref-type="bibr">50</xref>, <xref rid="iid370203-bib-0051" ref-type="bibr">51</xref>]. This study may elucidate why P2X7 knockout mice exhibit phenotypes that resemble the early stages of AMD. P2X7R plays a complex role in the pathology of AMD by modulating both leukocyte membrane fluidity and phagocytic function. While targeting P2X7R represents a promising therapeutic strategy, several challenges must be addressed, including mechanical complexity, drug selectivity, and clinical translation. Future research should focus on developing specific inhibitors and validating their efficacy in disease models that closely mimic human conditions.</p><p>The influx of Ca<sup>2+</sup> following the opening of P2X7R channels represents a significant consequence. This Ca<sup>2+</sup> influx may activate apoptotic pathways in neural cells, involving members of the caspase family in P2X7R&#x02010;mediated neural cell apoptosis [<xref rid="iid370203-bib-0052" ref-type="bibr">52</xref>]. Carver et al. demonstrated that P2X7R receptor knockout (KO) mice exhibit a reduction in AMD&#x02010;like defects and a decrease in the accumulation of microparticles (MPs) due to oxidative stress in Sod1 KO mice [<xref rid="iid370203-bib-0053" ref-type="bibr">53</xref>]. Furthermore, studies have indicated that amyloid&#x02010;&#x003b2; peptide (A&#x003b2;) induces caspase&#x02010;independent apoptosis by activating the P2X7R receptor in human retinal M&#x000fc;ller cells. The administration of P2X7R receptor antagonists has been shown to mitigate the toxicity of A&#x003b2; to the retina, thereby delaying the progression of AMD [<xref rid="iid370203-bib-0054" ref-type="bibr">54</xref>, <xref rid="iid370203-bib-0055" ref-type="bibr">55</xref>]. Recent research has highlighted the role of C3 in retinal degenerative diseases. Low levels of complement activation aid microglial phagocytosis and help maintain retinal homeostasis, while excessive activation may contribute to disease progression [<xref rid="iid370203-bib-0056" ref-type="bibr">56</xref>]. Future research could focus on these aspects to explore the mechanisms primarily responsible for AMD and to develop strategies to delay its progression.</p><p>In the pathological progression of AMD, the interplay and regulation between the P2X7R and various other molecular entities create a complex network that encompasses inflammation, apoptosis of neural cells, the release of growth factors, and additional factors. This intricate network collectively facilitates the advancement and progression of AMD. Through comprehensive investigations into the functions and interactions of P2X7R and its associated molecules, we can achieve a deeper understanding of the pathogenesis and pathology of AMD. Such insights may lead to novel strategies and methodologies for treating related disorders, including the identification of drug targets for P2X7R and the modulation of growth factor and neurotransmitter release.</p></sec><sec id="iid370203-sec-0120"><label>4.3</label><title>Retinitis Pigmentosa</title><p>Retinitis pigmentosa (RP) is a genetic ocular disorder characterized by the progressive degeneration of photoreceptors and a concomitant narrowing of the visual field. Despite extensive research, the underlying mechanisms of RP remain partially understood [<xref rid="iid370203-bib-0001" ref-type="bibr">1</xref>, <xref rid="iid370203-bib-0057" ref-type="bibr">57</xref>, <xref rid="iid370203-bib-0058" ref-type="bibr">58</xref>]. Recent investigations have indicated that ion channels and signaling pathways, particularly the P2X7R, may play a significant role in the pathophysiology of this condition. The P2X7R, an ion channel essential for retinal function, may influence retinal health and is implicated in the onset and progression of retinal pigmentary degeneration [<xref rid="iid370203-bib-0059" ref-type="bibr">59</xref>]. P2X7R is expressed in retinal pigment epithelial cells and is known to regulate inflammatory responses and apoptosis within retinal tissues. Dysregulation of P2X7R expression and function in the context of retinal pigmentary degeneration may exacerbate inflammatory processes and increase apoptotic activity, thereby contributing to the progression of the disease [<xref rid="iid370203-bib-0060" ref-type="bibr">60</xref>]. Recent studies have demonstrated that the P2X7R/CX3CL1/CX3CR1 signaling pathway is involved in a chemically induced RP rat model. Inhibition of this pathway has been shown to mitigate the overactivation of microglia and the subsequent release of inflammatory cytokines, which in turn alleviates photoreceptor degeneration associated with RP [<xref rid="iid370203-bib-0001" ref-type="bibr">1</xref>]. Furthermore, research conducted by Mart&#x000ed;nez&#x02010;Gil et al. has revealed elevated expression of P2X7RR in the rd10 mouse model of RP. These findings suggest that P2X7R&#x02010;mediated neuroinflammation plays a critical role in the progression of the disease and is associated with vision loss in patients with RP [<xref rid="iid370203-bib-0023" ref-type="bibr">23</xref>]. The activation of P2X7R can initiate intracellular signaling cascades that modulate various molecules and enzymes involved in inflammation, apoptosis, and oxidative stress. These signaling pathways may disrupt normal retinal cell function, thereby contributing to the development of retinal pigmentary degeneration.</p><p>Dysregulation of P2X7R expression and function may result in abnormalities in these processes, leading to increased inflammation and apoptosis in retinal cells. Such dysregulation may contribute to the progression of retinal pigmentary degeneration [<xref rid="iid370203-bib-0061" ref-type="bibr">61</xref>]. The involvement of P2X7R in retinal pigmentary degeneration is mediated through multiple pathways. Inflammation, a critical component of these pathways, is initiated by the activation of P2X7R, which leads to the release of inflammatory mediators that further exacerbate the inflammatory response. Apoptosis, another essential pathway, is also activated by P2X7R, resulting in the death of retinal cells. Collectively, these processes culminate in damage to retinal pigment cells and the subsequent progression of the disease [<xref rid="iid370203-bib-0062" ref-type="bibr">62</xref>].</p><p>Silverman et al. discovered that multiple complement components were significantly upregulated in the retinas of individuals with RP and in the rd10 mouse model. Further experiments demonstrated that the C3&#x02010;CR3 signaling pathway is a key regulator of the interaction between microglia and photoreceptors [<xref rid="iid370203-bib-0063" ref-type="bibr">63</xref>]. Additionally, studies have shown that oxidative stress plays a significant role in RP. The activation of P2X7R leads to the production of a substantial amount of ROS [<xref rid="iid370203-bib-0064" ref-type="bibr">64</xref>, <xref rid="iid370203-bib-0065" ref-type="bibr">65</xref>] and also triggers microglial activation. In the early stages of RP, microglial activation facilitates the clearance of cellular debris in the retina, thereby contributing to retinal homeostasis. However, in the later stages of the disease, sustained inflammation and ROS production can accelerate disease progression. This indicates that P2X7R&#x02010;induced microglial activation may have a dual role in RP [<xref rid="iid370203-bib-0066" ref-type="bibr">66</xref>]. Consequently, the complexity of the various adaptive and detrimental roles of microglia in retinal diseases may necessitate interventions aimed at achieving precise modulation rather than broad and complete inhibition, to attain optimal therapeutic outcomes.</p><p>Furthermore, genetic mutations and other hereditary factors may contribute to the pathogenesis of retinal pigmentary degeneration. Mutations in the P2X7R gene, along with other associated genes, can disrupt the normal functioning of P2X7R, resulting in its dysregulation and potentially exacerbating the disease process. To further elucidate the role of P2X7R in retinal pigmentary degeneration, additional research is necessary to investigate the molecular mechanisms that underlie inflammation, apoptosis, and other relevant pathways.</p></sec></sec><sec id="iid370203-sec-0130"><label>5</label><title>Genetic Variations in P2X7R</title><p>The genetic variations of P2X7R can significantly influence disease risk and susceptibility. Gain&#x02010;of&#x02010;function variants may lead to the overactivation of P2X7R, triggering excessive inflammatory responses or cell death, thereby increasing susceptibility to neurodegenerative and autoimmune diseases. It has been reported that the minor allele variants rs1718119 and rs2230912, when acting in concert, enhance receptor function, contributing to a pro&#x02010;inflammatory state associated with inflammatory diseases such as rheumatoid arthritis, Sj&#x000f6;gren's syndrome, and systemic juvenile idiopathic arthritis [<xref rid="iid370203-bib-0067" ref-type="bibr">67</xref>]. Conversely, loss&#x02010;of&#x02010;function variants may diminish P2X7R activity, resulting in reduced inflammatory responses or cell death, which may confer protection against certain diseases. An Australian case&#x02010;control cohort study found that a rare loss&#x02010;of&#x02010;function, low&#x02010;frequency allele of the P2X7 receptor single&#x02010;nucleotide polymorphism (SNP) rs28360457 is significantly associated with a protective effect against multiple sclerosis [<xref rid="iid370203-bib-0068" ref-type="bibr">68</xref>]. However, this variant may also disrupt the normal functioning of the immune system. Certain rare haplotypes, such as the combination of P2RX7 Gly150Arg and P2RX4 Tyr315Cys, can significantly alter P2X7R function, impairing the phagocytic ability of macrophages or microglia and thereby increasing susceptibility to diseases such as AMD [<xref rid="iid370203-bib-0069" ref-type="bibr">69</xref>].</p><p>Genetic variants of the P2X7R may serve as biomarkers for specific diseases, facilitating early diagnosis and risk assessment. The development of agonists or antagonists targeting P2X7R could offer novel strategies for treating related conditions. Although research on retinal diseases associated with mutations in the P2X7R gene is limited, this area may become a key focus for future studies. By integrating genomics, transcriptomics, and proteomics, we can conduct a comprehensive analysis of the functional impact of P2X7R gene variants and their roles in disease. Furthermore, personalized prevention and treatment strategies could be developed based on an individual's P2X7R genotype. Additionally, exploring the common and specific roles of P2X7R gene variants across different diseases may yield valuable insights.</p></sec><sec id="iid370203-sec-0140"><label>6</label><title>Potential Therapies Targeting P2X7R for Retinal Diseases</title><p>P2X7R is implicated in the pathogenesis and progression of various diseases, including retinal disorders. Recent research has focused on its potential therapeutic role in managing retinal diseases (Table&#x000a0;<xref rid="iid370203-tbl-0001" ref-type="table">1</xref>). Kong et al. demonstrated that 3TC, a nucleoside reverse transcriptase inhibitor, can concurrently decrease P2X7R levels in STZ&#x02010;induced mice, thereby mitigating pyroptosis, apoptosis, and high&#x02010;glucose&#x02010;induced retinal damage. Additionally, it was shown to alleviate damage to retinal endothelial cells induced by high glucose and lipopolysaccharides (LPS) In Vitro [<xref rid="iid370203-bib-0019" ref-type="bibr">19</xref>]. Yang et al. reported that H3 relaxin inhibits apoptosis in HRMECs and the release of inflammatory mediators triggered by AGE. This effect is mediated through the inhibition of the P2X7R/NLRP3 signaling pathway [<xref rid="iid370203-bib-0033" ref-type="bibr">33</xref>]. Furthermore, dihydrotanshinone has been identified as a novel inhibitor of P2X7R, with studies evaluating its protective effects against high glucose (HG) and BzATP&#x02010;induced damage in an In Vitro BRB model comprising retinal pericytes, astrocytes, and endothelial cells. Treatment with dihydrotanshinone was found to preserve BRB integrity from HG/BzATP&#x02010;induced damage and to reduce ROS production [<xref rid="iid370203-bib-0039" ref-type="bibr">39</xref>]. Additionally, a study indicated that the inhibitor JNJ47965567 effectively mitigates the detrimental effects of high glucose on human pericytes [<xref rid="iid370203-bib-0070" ref-type="bibr">70</xref>]. The findings indicate that P2X7 receptor inhibitors, specifically A740003 and AZ10606120, provide protective effects against hyperglycemia&#x02010;induced damage in HREC by preventing lactate dehydrogenase (LDH) release and safeguarding the BRB. This intervention significantly diminishes hyperglycemia&#x02010;induced expression and release of IL&#x02010;1&#x003b2; [<xref rid="iid370203-bib-0071" ref-type="bibr">71</xref>]. Research conducted by Clapp et al. demonstrated that the blockade of P2X7R in STZ&#x02010;induced diabetic rats effectively reversed the increased retinal vascular permeability, VEGF accumulation, and expression of IL&#x02010;6, without affecting blood glucose levels. The authors proposed that P2X7 receptor blockade may represent a viable therapeutic strategy for addressing early microvascular alterations associated with DR [<xref rid="iid370203-bib-0028" ref-type="bibr">28</xref>].</p><table-wrap position="float" id="iid370203-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>List of the potential agents of P2X7R in retinal diseases.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Disease</th><th align="center" valign="bottom" rowspan="1" colspan="1">Agent</th><th align="center" valign="bottom" rowspan="1" colspan="1">Target</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pathway</th><th align="center" valign="bottom" rowspan="1" colspan="1">Effect</th><th align="center" valign="bottom" rowspan="1" colspan="1">Animal/cell model</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reference</th><th align="center" valign="bottom" rowspan="1" colspan="1">Limitation</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top" colspan="1">Diabetic retinopathy</td><td align="center" valign="top" rowspan="1" colspan="1">3TC (transcriptase inhibitor lamivudine)</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, NLRP3</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">C57BL/6J mice/mouse retinal endothelial cells</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0019" ref-type="bibr">19</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">No elucidate P2X7 from an ion channel to a pore</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3TC</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">C57BL/6J mice diabetes</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0072" ref-type="bibr">72</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">NO experiment in cell</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">H3 relaxin</td><td align="center" valign="top" rowspan="1" colspan="1">AGE</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, NLRP3</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">Human retinal microvascular endothelial cells/Rat</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0033" ref-type="bibr">33</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Mechanism not discussed in depth</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Dihydrotanshinone/JNJ47965567</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;ROS/P2X7R/ZO&#x02010;1</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">Human retinal endothelial cells, pericytes, and astrocytes</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0039" ref-type="bibr">39</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">NO experiment In Vivo</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">AZ10606120/A740063</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, VEGF</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">Wistar rats</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0028" ref-type="bibr">28</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Mechanism not discussed in depth</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">JNJ47965567</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R/IL&#x02010;1&#x003b2;</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">Human retinal pericytes</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0070" ref-type="bibr">70</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Experimental methods lack diversity</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">A438079</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;CD40, P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">Human RECs and Muller</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0031" ref-type="bibr">31</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">NO experiment In Vivo</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">AZ11645373/A438079</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, P2X4R</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">HUVECs</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0036" ref-type="bibr">36</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">NO experiment In Vivo</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">Age&#x02010;related macular degeneration</td><td align="center" valign="top" rowspan="1" colspan="1">Berberine</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, TNF&#x02010;&#x003b1;,</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R KO mice/C57BL/6J mice</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0022" ref-type="bibr">22</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">No experiment in cell</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3TC</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">IL&#x02010;1&#x003b2;/</td><td align="center" valign="top" rowspan="1" colspan="1">Ineffective</td><td align="center" valign="top" rowspan="1" colspan="1">HIV infected patients</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0003" ref-type="bibr">3</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Uncertainty in intraocular drug concentration</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">A438079/AZ10606120</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, Membrane fluidity</td><td align="center" valign="top" rowspan="1" colspan="1">Deleterious</td><td align="center" valign="top" rowspan="1" colspan="1">patients with AMD/P2X7 KO mice</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0050" ref-type="bibr">50</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Not clear molecular pathways</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">/</td><td align="center" valign="top" rowspan="1" colspan="1">/</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">Deleterious</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7&#x02010;null mice</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0049" ref-type="bibr">49</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">No experiment in cell</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">A740003</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, IL&#x02010;1&#x003b2;, VEGF</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">ARPE&#x02010;19/C57BL/6 mice</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0047" ref-type="bibr">47</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Not clear direct interaction of P2X7R and NLRP3</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">A740003</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, NF&#x02010;KB, NLRP3</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R KO mice /Human and mouse RPE</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0046" ref-type="bibr">46</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Experimental methods lack diversity</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age&#x02010;related macular degeneration</td><td align="center" valign="top" rowspan="1" colspan="1">A740003</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;ROS</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">Human ARPE&#x02010;19</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0073" ref-type="bibr">73</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">NO experiment In Vivo</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Saffron</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, NF&#x02010;KB, NLRP3</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Mouse retinal photoreceptor&#x02010;derived 661W cell</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0006" ref-type="bibr">6</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">NO experiment In Vivo</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Retinitis pigmentosa</td><td align="center" valign="top" rowspan="1" colspan="1">Bujing Yishi tablets</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R, CX3CL1, CX3CR1</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">MNU&#x02010;induced RP rats,</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0001" ref-type="bibr">1</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Complement molecules should be explore</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">pyridoxal&#x02010;phosphate&#x02010;6&#x02010;azophenyl2&#x02032;,4&#x02032;&#x02010;disulfonic acid (PPADS)</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02193;P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">Rats and rd1 mice</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0062" ref-type="bibr">62</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Mechanism not discussed in depth</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Brilliant blue G</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R, caspase&#x02010;8</td><td align="center" valign="top" rowspan="1" colspan="1">Protective</td><td align="center" valign="top" rowspan="1" colspan="1">P2X7R KO mic and mouse primary retinal cell e</td><td align="center" valign="top" rowspan="1" colspan="1">[<xref rid="iid370203-bib-0060" ref-type="bibr">60</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Only part of the mechanisms</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Berberine (BBR) has been shown to reduce the overexpression of P2X7 receptors in retinal ganglion cells and M&#x000fc;ller cells in a mouse model of AMD. BBR also mitigated retinal light damage by decreasing histological injury, cell death, and inflammatory responses [<xref rid="iid370203-bib-0022" ref-type="bibr">22</xref>]. Additionally, Bujing Yishi tablets (BJYS), a traditional Chinese herbal remedy, have been reported to slow the progression of RP by inhibiting the P2X7R/CX3CL1/CX3CR1 signaling pathway [<xref rid="iid370203-bib-0001" ref-type="bibr">1</xref>]. A recent retrospective clinical study found no statistically significant differences in the prevalence of early&#x02010;to&#x02010;intermediate AMD, geographic atrophy, or exudative AMD between HIV patients who utilized P2X7 receptor inhibitors and those who did not [<xref rid="iid370203-bib-0003" ref-type="bibr">3</xref>]. Consistent with previous animal studies, the result showed no statistically significant differences, a possible reason for the dosage may be that it is inadequate to reach an effective P2X7R inhibitory concentration in the retina. Furthermore, HIV patients often display elevated levels of inflammation and immune system abnormalities, which may independently affect the progression of ARMD, irrespective of the role of P2X7R.</p></sec><sec id="iid370203-sec-0150"><label>7</label><title>Challenges in the Development of P2X7R Inhibitors</title><p>P2X7R inhibitors have demonstrated promising potential in various animal disease models, particularly in the contexts of neuroinflammation and neurodegenerative diseases; however, their clinical application faces significant challenges. Notable differences exist between animal models and humans, complicating the translation of preclinical findings to clinical settings. Many P2X7R inhibitors also exhibit off&#x02010;target effects by inhibiting other P2X receptor subtypes, which may lead to unintended consequences. Additionally, some P2X7R inhibitors suffer from low stability and bioavailability In Vivo, limiting their clinical utility. Given that P2X7R plays a role in normal physiological processes, long&#x02010;term inhibition may result in unforeseen side effects. Furthermore, the mechanisms of P2X7R action may vary across different diseases, indicating that a single inhibitor may not be universally applicable to all indications.</p><p>To address these challenges, future efforts should concentrate on developing highly selective inhibitors through structural optimization and drug design. Combining P2X7R inhibitors with other therapeutic approaches, such as anti&#x02010;VEGF agents or antioxidants, may enhance treatment efficacy. Furthermore, screening patient populations based on P2X7R activity or genetic profiles could facilitate personalized treatment strategies. Despite these promising avenues, significant obstacles remain, and the journey toward the clinical application of P2X7R inhibitors is still lengthy and intricate.</p></sec><sec sec-type="conclusions" id="iid370203-sec-0160"><label>8</label><title>Conclusion</title><p>In summary, the investigation of P2X7R in relation to retinal diseases holds significant scientific and clinical importance. P2X7R is a vital component of the P2X receptor family, playing a key role in various physiological processes, particularly in immune regulation and cellular signaling within the retina (Figure&#x000a0;<xref rid="iid370203-fig-0001" ref-type="fig">1</xref>). A comprehensive understanding of the diverse functions of P2X7R in both health and disease contributes to our knowledge of its potential as a therapeutic target. Future research initiatives centered on P2X7R may provide valuable insights into novel treatment strategies for a variety of conditions, including inflammatory diseases and retinal disorders.</p><fig position="float" fig-type="Figure" id="iid370203-fig-0001"><label>Figure 1</label><caption><p>Molecular signaling pathway of P2X7R in retina.</p></caption><graphic xlink:href="IID3-13-e70203-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="iid370203-sec-0170"><title>Author Contributions</title><p>
<bold>Chunli Li:</bold> writing &#x02013; original draft, and funding acquisition. <bold>Binsheng Wang:</bold> conceptualization, writing &#x02013; review and editing, supervision.</p></sec><sec id="iid370203-sec-0190"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec id="iid370203-sec-0200"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="iid370203-sec-0210"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="iid370203-sec-0180"><title>Acknowledgments</title><p>This study was funded by the Natural Science Foundation of Gansu Province (22JR5RA971).</p></ack><sec sec-type="data-availability" id="iid370203-sec-0230"><title>Data Availability Statement</title><p>The authors have nothing to report.</p></sec><ref-list content-type="cited-references" id="iid370203-bibl-0001"><title>References</title><ref id="iid370203-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="iid370203-cit-0001">
<string-name>
<given-names>Y.</given-names>
<surname>Qi</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Liang</surname>
</string-name>, et al., &#x0201c;<article-title>Bujing Yishi Tablets Alleviate Photoreceptor Cells Death via the P2X7R/CX3CL1/CX3CR1 Pathway in <italic toggle="yes">Retinitis pigmentosa</italic> Rats</article-title>,&#x0201d; <source>Phytomedicine</source>
<volume>115</volume> (<year>2023</year>): <elocation-id>154828</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.phymed.2023.154828</pub-id>.<pub-id pub-id-type="pmid">37116386</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="iid370203-cit-0002">
<string-name>
<given-names>C. C.</given-names>
<surname>Lepre</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Russo</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Trotta</surname>
</string-name>, et al., &#x0201c;<article-title>Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>24</volume> (<year>2023</year>): <elocation-id>9721</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms24119721</pub-id>.<pub-id pub-id-type="pmid">37298672</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="iid370203-cit-0003">
<string-name>
<given-names>K. M.</given-names>
<surname>Woo</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Mahrous</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>D'Amico</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kiss</surname>
</string-name>, and <string-name>
<given-names>K. D.</given-names>
<surname>Kovacs</surname>
</string-name>, &#x0201c;<article-title>Prevalence of Age&#x02010;Related Macular Degeneration in Patients With Chronic Exposure to P2X7R Inhibitors</article-title>,&#x0201d; <source>Graefe's Archive for Clinical and Experimental Ophthalmology</source>
<volume>262</volume> (<year>2024</year>): <fpage>3493</fpage>&#x02013;<lpage>3499</lpage>, <pub-id pub-id-type="doi">10.1007/s00417-024-06507-9</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="iid370203-cit-0004">
<string-name>
<given-names>S. K. F.</given-names>
<surname>De Salis</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Chen</surname>
</string-name>, et al., &#x0201c;<article-title>Alternatively Spliced Isoforms of the P2X7 Receptor: Structure, Function and Disease Associations</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume> (<year>2022</year>): <elocation-id>8174</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms23158174</pub-id>.<pub-id pub-id-type="pmid">35897750</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="iid370203-cit-0005">
<string-name>
<given-names>S.</given-names>
<surname>Chavda</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>Luthert</surname>
</string-name>, and <string-name>
<given-names>T. E.</given-names>
<surname>Salt</surname>
</string-name>, &#x0201c;<article-title>P2X<sub>7</sub>R Modulation of Visually Evoked Synaptic Responses in the Retina</article-title>,&#x0201d; <source>Purinergic Signalling</source>
<volume>12</volume> (<year>2016</year>): <fpage>611</fpage>&#x02013;<lpage>625</lpage>, <pub-id pub-id-type="doi">10.1007/s11302-016-9522-7</pub-id>.<pub-id pub-id-type="pmid">27393519</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="iid370203-cit-0006">
<string-name>
<given-names>L.</given-names>
<surname>Corso</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Cavallero</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Baroni</surname>
</string-name>, et al., &#x0201c;<article-title>Saffron Reduces ATP&#x02010;Induced Retinal Cytotoxicity by Targeting P2X7 Receptors</article-title>,&#x0201d; <source>Purinergic Signalling</source>
<volume>12</volume> (<year>2016</year>): <fpage>161</fpage>&#x02013;<lpage>174</lpage>, <pub-id pub-id-type="doi">10.1007/s11302-015-9490-3</pub-id>.<pub-id pub-id-type="pmid">26739703</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="iid370203-cit-0007">
<string-name>
<given-names>A.</given-names>
<surname>Pariente</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pel&#x000e1;ez</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ochoa</surname>
</string-name>, et al., &#x0201c;<article-title>Targeting 7KCh&#x02010;Induced Cell Death Response Mediated by p38, P2X7 and GSDME in Retinal Pigment Epithelium Cells With Sterculic Acid</article-title>,&#x0201d; <source>Pharmaceutics</source>
<volume>15</volume> (<year>2023</year>): <elocation-id>2590</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics15112590</pub-id>.<pub-id pub-id-type="pmid">38004569</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="iid370203-cit-0008">
<string-name>
<given-names>V.</given-names>
<surname>Maneu</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Lax</surname>
</string-name>, <string-name>
<given-names>A. M. G.</given-names>
<surname>De Diego</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Cuenca</surname>
</string-name>, and <string-name>
<given-names>A. G.</given-names>
<surname>Garc&#x000ed;a</surname>
</string-name>, &#x0201c;<article-title>Combined Drug Triads for Synergic Neuroprotection in Retinal Degeneration</article-title>,&#x0201d; <source>Biomedicine &#x00026; Pharmacotherapy</source>
<volume>149</volume> (<year>2022</year>): <elocation-id>112911</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.biopha.2022.112911</pub-id>.<pub-id pub-id-type="pmid">36068774</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="iid370203-cit-0009">
<string-name>
<given-names>R. A.</given-names>
<surname>North</surname>
</string-name>, &#x0201c;<article-title>Molecular Physiology of P2X Receptors</article-title>,&#x0201d; <source>Physiological Reviews</source>
<volume>82</volume> (<year>2002</year>): <fpage>1013</fpage>&#x02013;<lpage>1067</lpage>, <pub-id pub-id-type="doi">10.1152/physrev.00015.2002</pub-id>.<pub-id pub-id-type="pmid">12270951</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="iid370203-cit-0010">
<string-name>
<given-names>S. D.</given-names>
<surname>Skaper</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Debetto</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Giusti</surname>
</string-name>, &#x0201c;<article-title>The P2X<sub>7</sub>Purinergic Receptor: From Physiology to Neurological Disorders</article-title>,&#x0201d; <source>FASEB Journal</source>
<volume>24</volume> (<year>2009</year>): <fpage>337</fpage>&#x02013;<lpage>345</lpage>, <pub-id pub-id-type="doi">10.1096/fj.09-138883</pub-id>.<pub-id pub-id-type="pmid">19812374</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="iid370203-cit-0011">
<string-name>
<given-names>M.</given-names>
<surname>Tassetto</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Scialdone</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Solini</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Di Virgilio</surname>
</string-name>, &#x0201c;<article-title>The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>22</volume> (<year>2021</year>): <elocation-id>7110</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms22137110</pub-id>.<pub-id pub-id-type="pmid">34281162</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="iid370203-cit-0012">
<string-name>
<given-names>K. E.</given-names>
<surname>Ronning</surname>
</string-name>, <string-name>
<given-names>P.&#x02010;A.</given-names>
<surname>D&#x000e9;chelle&#x02010;Marquet</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Che</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Guillonneau</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Sennlaub</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Delarasse</surname>
</string-name>, &#x0201c;<article-title>The P2X7 Receptor, a Multifaceted Receptor in Alzheimer's Disease</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>24</volume> (<year>2023</year>): <elocation-id>11747</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms241411747</pub-id>.<pub-id pub-id-type="pmid">37511507</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="iid370203-cit-0013">
<string-name>
<given-names>X.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Huang</surname>
</string-name>, et al., &#x0201c;<article-title>Unlocking the Therapeutic Potential of P2X7 Receptor: A Comprehensive Review of Its Role in Neurodegenerative Disorders</article-title>,&#x0201d; <source>Frontiers in Pharmacology</source>
<volume>15</volume> (<year>2024</year>): <elocation-id>1450704</elocation-id>, <pub-id pub-id-type="doi">10.3389/fphar.2024.1450704</pub-id>.<pub-id pub-id-type="pmid">39139642</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="iid370203-cit-0014">
<string-name>
<given-names>C.</given-names>
<surname>Agliardi</surname>
</string-name>, <string-name>
<given-names>F. R.</given-names>
<surname>Guerini</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Zanzottera</surname>
</string-name>, et al., &#x0201c;<article-title>Increased Concentrations of P2X7R in Oligodendrocyte Derived Extracellular Vesicles of Multiple Sclerosis Patients</article-title>,&#x0201d; <source>Neurobiology of Disease</source>
<volume>199</volume> (<year>2024</year>): <elocation-id>106601</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.nbd.2024.106601</pub-id>.<pub-id pub-id-type="pmid">38996986</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="iid370203-cit-0015">
<string-name>
<given-names>V.</given-names>
<surname>Bandara</surname>
</string-name>, <string-name>
<given-names>V. M.</given-names>
<surname>Niktaras</surname>
</string-name>, <string-name>
<given-names>V. J.</given-names>
<surname>Willett</surname>
</string-name>, et al., &#x0201c;<article-title>Engineered CAR&#x02010;T Cells Targeting the Non&#x02010;Functional P2X Purinoceptor 7 (P2X7) Receptor as a Novel Treatment for Ovarian Cancer</article-title>,&#x0201d; <source>Clinical &#x00026; Translational Immunology</source>
<volume>13</volume> (<year>2024</year>): <elocation-id>e1512</elocation-id>, <pub-id pub-id-type="doi">10.1002/cti2.1512</pub-id>.<pub-id pub-id-type="pmid">38800555</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="iid370203-cit-0016">
<string-name>
<given-names>P.</given-names>
<surname>Pelegrin</surname>
</string-name>, &#x0201c;<article-title>P2X7 Receptor and the NLRP3 Inflammasome: Partners in Crime</article-title>,&#x0201d; <source>Biochemical Pharmacology</source>
<volume>187</volume> (<year>2021</year>): <elocation-id>114385</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.bcp.2020.114385</pub-id>.<pub-id pub-id-type="pmid">33359010</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="iid370203-cit-0017">
<string-name>
<given-names>L. E.</given-names>
<surname>Browne</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Compan</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Bragg</surname>
</string-name>, and <string-name>
<given-names>R. A.</given-names>
<surname>North</surname>
</string-name>, &#x0201c;<article-title>P2X7 Receptor Channels Allow Direct Permeation of Nanometer&#x02010;Sized Dyes</article-title>,&#x0201d; <source>Journal of Neuroscience</source>
<volume>33</volume> (<year>2013</year>): <fpage>3557</fpage>&#x02013;<lpage>3566</lpage>, <pub-id pub-id-type="doi">10.1523/jneurosci.2235-12.2013</pub-id>.<pub-id pub-id-type="pmid">23426683</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="iid370203-cit-0018">
<string-name>
<given-names>B. J.</given-names>
<surname>Schmiedel</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Singh</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Madrigal</surname>
</string-name>, et al., &#x0201c;<article-title>Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression</article-title>,&#x0201d; <source>Cell</source>
<volume>175</volume> (<year>2018</year>): <fpage>1701</fpage>&#x02013;<lpage>1715.e16</lpage>, <pub-id pub-id-type="doi">10.1016/j.cell.2018.10.022</pub-id>.<pub-id pub-id-type="pmid">30449622</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="iid370203-cit-0019">
<string-name>
<given-names>H.</given-names>
<surname>Kong</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Song</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Cui</surname>
</string-name>, &#x0201c;<article-title>Targeted P2X7/NLRP3 Signaling Pathway Against Inflammation, Apoptosis, and Pyroptosis of Retinal Endothelial Cells in Diabetic Retinopathy</article-title>,&#x0201d; <source>Cell Death &#x00026; Disease</source>
<volume>13</volume> (<year>2022</year>): <fpage>336</fpage>, <pub-id pub-id-type="doi">10.1038/s41419-022-04786-w</pub-id>.<pub-id pub-id-type="pmid">35410316</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="iid370203-cit-0020">
<string-name>
<given-names>F.</given-names>
<surname>Virgilio</surname>
</string-name>, &#x0201c;<article-title>P2X Receptors and Inflammation</article-title>,&#x0201d; <source>Current Medicinal Chemistry</source>
<volume>22</volume> (<year>2015</year>): <fpage>866</fpage>&#x02013;<lpage>877</lpage>, <pub-id pub-id-type="doi">10.2174/0929867322666141210155311</pub-id>.<pub-id pub-id-type="pmid">25524252</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="iid370203-cit-0021">
<string-name>
<given-names>J.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Hu</surname>
</string-name>, et al., &#x0201c;<article-title>ATP Ion Channel P2X Purinergic Receptors in Inflammation Response</article-title>,&#x0201d; <source>Biomedicine &#x00026; Pharmacotherapy</source>
<volume>158</volume> (<year>2023</year>): <elocation-id>114205</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.biopha.2022.114205</pub-id>.<pub-id pub-id-type="pmid">36916431</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="iid370203-cit-0022">
<string-name>
<given-names>S. S.</given-names>
<surname>Ye</surname>
</string-name>, <string-name>
<given-names>J. N.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Y. F.</given-names>
<surname>Zhao</surname>
</string-name>, et al., &#x0201c;<article-title>Purinergic P2X7 Receptor Involves in Anti&#x02010;Retinal Photodamage Effects of Berberine</article-title>,&#x0201d; <source>Purinergic Signalling</source> (<year>2024</year>), <pub-id pub-id-type="doi">10.1007/s11302-024-09999-6</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="iid370203-cit-0023">
<string-name>
<given-names>N.</given-names>
<surname>Mart&#x000ed;nez&#x02010;Gil</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Kutsyr</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Noailles</surname>
</string-name>, et al., &#x0201c;<article-title>Purinergic Receptors P2X7 and P2X4 as Markers of Disease Progression in the rd10 Mouse Model of Inherited Retinal Dystrophy</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume> (<year>2022</year>): <elocation-id>14758</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms232314758</pub-id>.<pub-id pub-id-type="pmid">36499084</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="iid370203-cit-0024">
<string-name>
<given-names>H.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Nie</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Fang</surname>
</string-name>, et al., &#x0201c;<article-title>M&#x000fc;ller Cells Under Hydrostatic Pressure Modulate Retinal Cell Survival viaTRPV1/PLC&#x003b3;1 Complex&#x02010;Mediated Calcium Influx in Experimental Glaucoma</article-title>,&#x0201d; <source>FEBS Journal</source>
<volume>291</volume> (<year>2024</year>): <fpage>2703</fpage>&#x02013;<lpage>2714</lpage>, <pub-id pub-id-type="doi">10.1111/febs.17075</pub-id>.<pub-id pub-id-type="pmid">38390745</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="iid370203-cit-0025">
<string-name>
<given-names>J.</given-names>
<surname>Ning</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Pan</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Yang</surname>
</string-name>, et al., &#x0201c;<article-title>Melatonin Attenuates Diabetic Retinopathy by Regulating EndMT of Retinal Vascular Endothelial Cells via Inhibiting the HDAC7/FOXO1/ZEB1 Axis</article-title>,&#x0201d; <source>Journal of Pineal Research</source>
<volume>76</volume> (<year>2024</year>): <elocation-id>e13008</elocation-id>, <pub-id pub-id-type="doi">10.1111/jpi.13008</pub-id>.<pub-id pub-id-type="pmid">39300782</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="iid370203-cit-0026">
<string-name>
<given-names>A.</given-names>
<surname>Solini</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Chiozzi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Morelli</surname>
</string-name>, et al., &#x0201c;<article-title>Enhanced P2X<sub>7</sub> Activity in Human Fibroblasts From Diabetic Patients: A Possible Pathogenetic Mechanism for Vascular Damage in Diabetes</article-title>,&#x0201d; <source>Arteriosclerosis, Thrombosis, and Vascular Biology</source>
<volume>24</volume> (<year>2004</year>): <fpage>1240</fpage>&#x02013;<lpage>1245</lpage>, <pub-id pub-id-type="doi">10.1161/01.ATV.0000133193.11078.c0</pub-id>.<pub-id pub-id-type="pmid">15155383</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="iid370203-cit-0027">
<string-name>
<given-names>H.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Nie</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Xiong</surname>
</string-name>, et al., &#x0201c;<article-title>P2X<sub>7</sub> Receptor Expression in Peripheral Blood Monocytes Is Correlated With Plasma C&#x02010;Reactive Protein and Cytokine Levels in Patients With Type 2 Diabetes Mellitus: A Preliminary Report</article-title>,&#x0201d; <source>Inflammation</source>
<volume>38</volume> (<year>2015</year>): <fpage>2076</fpage>&#x02013;<lpage>2081</lpage>, <pub-id pub-id-type="doi">10.1007/s10753-015-0189-y</pub-id>.<pub-id pub-id-type="pmid">26021292</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="iid370203-cit-0028">
<string-name>
<given-names>C.</given-names>
<surname>Clapp</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Diaz&#x02010;Lezama</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Adan&#x02010;Castro</surname>
</string-name>, et al., &#x0201c;<article-title>Pharmacological Blockade of the P2X7 Receptor Reverses Retinal Damage in a Rat Model of type 1 Diabetes</article-title>,&#x0201d; <source>Acta Diabetologica</source>
<volume>56</volume> (<year>2019</year>): <fpage>1031</fpage>&#x02013;<lpage>1036</lpage>, <pub-id pub-id-type="doi">10.1007/s00592-019-01343-4</pub-id>.<pub-id pub-id-type="pmid">30982154</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="iid370203-cit-0029">
<string-name>
<given-names>T.</given-names>
<surname>Sugiyama</surname>
</string-name>, &#x0201c;<article-title>Role of P2X<sub>7</sub> Receptors in the Development of Diabetic Retinopathy</article-title>,&#x0201d; <source>World Journal of Diabetes</source>
<volume>5</volume> (<year>2014</year>): <fpage>141</fpage>&#x02013;<lpage>145</lpage>, <pub-id pub-id-type="doi">10.4239/wjd.v5.i2.141</pub-id>.<pub-id pub-id-type="pmid">24748927</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="iid370203-cit-0030">
<string-name>
<given-names>J. A. C.</given-names>
<surname>Portillo</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Lopez Corcino</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Miao</surname>
</string-name>, et al., &#x0201c;<article-title>CD40 in Retinal M&#x000fc;ller Cells Induces P2X<sub>7</sub>&#x02010;Dependent Cytokine Expression in Macrophages/Microglia in Diabetic Mice and Development of Early Experimental Diabetic Retinopathy</article-title>,&#x0201d; <source>Diabetes</source>
<volume>66</volume> (<year>2017</year>): <fpage>483</fpage>&#x02013;<lpage>493</lpage>, <pub-id pub-id-type="doi">10.2337/db16-0051</pub-id>.<pub-id pub-id-type="pmid">27474370</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="iid370203-cit-0031">
<string-name>
<given-names>J. A. C.</given-names>
<surname>Portillo</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Lopez Corcino</surname>
</string-name>, <string-name>
<given-names>G. R.</given-names>
<surname>Dubyak</surname>
</string-name>, <string-name>
<given-names>T. S.</given-names>
<surname>Kern</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Matsuyama</surname>
</string-name>, and <string-name>
<given-names>C. S.</given-names>
<surname>Subauste</surname>
</string-name>, &#x0201c;<article-title>Ligation of CD40 in Human M&#x000fc;ller Cells Induces P2X<sub>7</sub> Receptor&#x02010;Dependent Death of Retinal Endothelial Cells</article-title>,&#x0201d; <source>Investigative Opthalmology &#x00026; Visual Science</source>
<volume>57</volume> (<year>2016</year>): <fpage>6278</fpage>&#x02013;<lpage>6286</lpage>, <pub-id pub-id-type="doi">10.1167/iovs.16-20301</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="iid370203-cit-0032">
<string-name>
<given-names>O. O.</given-names>
<surname>Mugisho</surname>
</string-name>, <string-name>
<given-names>C. R.</given-names>
<surname>Green</surname>
</string-name>, <string-name>
<given-names>D. T.</given-names>
<surname>Kho</surname>
</string-name>, et al., &#x0201c;<article-title>The Inflammasome Pathway Is Amplified and Perpetuated in an Autocrine Manner Through Connexin43 Hemichannel Mediated ATP Release</article-title>,&#x0201d; <source>Biochimica et Biophysica Acta (BBA)&#x02014;General Subjects</source>
<volume>1862</volume> (<year>2018</year>): <fpage>385</fpage>&#x02013;<lpage>393</lpage>, <pub-id pub-id-type="doi">10.1016/j.bbagen.2017.11.015</pub-id>.<pub-id pub-id-type="pmid">29158134</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="iid370203-cit-0033">
<string-name>
<given-names>K.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, et al., &#x0201c;<article-title>H3 Relaxin Alleviates Migration, Apoptosis and Pyroptosis Through P2X7R&#x02010;Mediated Nucleotide Binding Oligomerization Domain&#x02010;Like Receptor Protein 3 Inflammasome Activation in Retinopathy Induced by Hyperglycemia</article-title>,&#x0201d; <source>Frontiers in Pharmacology</source>
<volume>11</volume> (<year>2020</year>): <elocation-id>603689</elocation-id>, <pub-id pub-id-type="doi">10.3389/fphar.2020.603689</pub-id>.<pub-id pub-id-type="pmid">33584279</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="iid370203-cit-0034">
<string-name>
<given-names>C. S.</given-names>
<surname>Subauste</surname>
</string-name>, &#x0201c;<article-title>The CD40&#x02010;ATP&#x02010;P2X<sub>7</sub> Receptor Pathway: Cell to Cell Cross&#x02010;Talk to Promote Inflammation and Programmed Cell Death of Endothelial Cells</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>10</volume> (<year>2019</year>): <elocation-id>2958</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2019.02958</pub-id>.<pub-id pub-id-type="pmid">31921199</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="iid370203-cit-0035">
<string-name>
<given-names>J. S.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Daw</surname>
</string-name>, <string-name>
<given-names>J. A. C.</given-names>
<surname>Portillo</surname>
</string-name>, and <string-name>
<given-names>C. S.</given-names>
<surname>Subauste</surname>
</string-name>, &#x0201c;<article-title>CD40 Expressed in Endothelial Cells Promotes Upregulation of ICAM&#x02010;1 But Not Pro&#x02010;Inflammatory Cytokines, NOS2 and P2X<sub>7</sub> in the Diabetic Retina</article-title>,&#x0201d; <source>Investigative Opthalmology &#x00026; Visual Science</source>
<volume>62</volume> (<year>2021</year>): <elocation-id>22</elocation-id>, <pub-id pub-id-type="doi">10.1167/iovs.62.12.22</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="iid370203-cit-0036">
<string-name>
<given-names>R.</given-names>
<surname>Sathanoori</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Sw&#x000e4;rd</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Olde</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Erlinge</surname>
</string-name>, &#x0201c;<article-title>The ATP Receptors P2X7 and P2X4 Modulate High Glucose and Palmitate&#x02010;Induced Inflammatory Responses in Endothelial Cells</article-title>,&#x0201d; <source>PLoS One</source>
<volume>10</volume> (<year>2015</year>): <elocation-id>e0125111</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0125111</pub-id>.<pub-id pub-id-type="pmid">25938443</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="iid370203-cit-0037">
<string-name>
<given-names>M.</given-names>
<surname>Shibata</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Ishizaki</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Zhang</surname>
</string-name>, et al., &#x0201c;<article-title>Purinergic Vasotoxicity: Role of the Pore/Oxidant/K<sub>ATP</sub> Channel/Ca<sup>2+</sup> Pathway in P2X<sub>7</sub>&#x02010;Induced Cell Death in Retinal Capillaries</article-title>,&#x0201d; <source>Vision</source>
<volume>2</volume> (<year>2018</year>): <elocation-id>25</elocation-id>, <pub-id pub-id-type="doi">10.3390/vision2030025</pub-id>.<pub-id pub-id-type="pmid">30288454</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="iid370203-cit-0038">
<string-name>
<given-names>Q.</given-names>
<surname>Kang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Dai</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Jiang</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Yu</surname>
</string-name>, &#x0201c;<article-title>Advanced Glycation End Products in Diabetic Retinopathy and Phytochemical Therapy</article-title>,&#x0201d; <source>Frontiers in Nutrition</source>
<volume>9</volume> (<year>2022</year>): <elocation-id>1037186</elocation-id>, <pub-id pub-id-type="doi">10.3389/fnut.2022.1037186</pub-id>.<pub-id pub-id-type="pmid">36466410</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="iid370203-cit-0039">
<string-name>
<given-names>C. G.</given-names>
<surname>Fresta</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Caruso</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fidilio</surname>
</string-name>, et al., &#x0201c;<article-title>Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood&#x02010;Retinal Barrier Integrity via P2X7 Receptor</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>21</volume> (<year>2020</year>): <elocation-id>9305</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms21239305</pub-id>.<pub-id pub-id-type="pmid">33291318</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="iid370203-cit-0040">
<string-name>
<given-names>T.</given-names>
<surname>Sugiyama</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kobayashi</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Kawamura</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>D. G.</given-names>
<surname>Puro</surname>
</string-name>, &#x0201c;<article-title>Enhancement of P2X<sub>7</sub>&#x02010;Induced Pore Formation and Apoptosis: An Early Effect of Diabetes on the Retinal Microvasculature</article-title>,&#x0201d; <source>Investigative Opthalmology &#x00026; Visual Science</source>
<volume>45</volume> (<year>2004</year>): <fpage>1026</fpage>&#x02013;<lpage>1032</lpage>, <pub-id pub-id-type="doi">10.1167/iovs.03-1062</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="iid370203-cit-0041">
<string-name>
<given-names>G.</given-names>
<surname>Corr&#x000ea;a</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Almeida Lindenberg</surname>
</string-name>, <string-name>
<given-names>A. C. A.</given-names>
<surname>Moreira&#x02010;Souza</surname>
</string-name>, et al., &#x0201c;<article-title>Inflammatory Early Events Associated to the Role of P2X7 Receptor in Acute Murine Toxoplasmosis</article-title>,&#x0201d; <source>Immunobiology</source>
<volume>222</volume> (<year>2017</year>): <fpage>676</fpage>&#x02013;<lpage>683</lpage>, <pub-id pub-id-type="doi">10.1016/j.imbio.2016.12.007</pub-id>.<pub-id pub-id-type="pmid">28069296</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="iid370203-cit-0042">
<string-name>
<given-names>C.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>He</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Wang</surname>
</string-name>, et al., &#x0201c;<article-title>Virus&#x02010;Triggered ATP Release Limits Viral Replication Through Facilitating IFN&#x02010;&#x003b2; Production in a P2X7&#x02010;Dependent Manner</article-title>,&#x0201d; <source>Journal of Immunology</source>
<volume>199</volume> (<year>2017</year>): <fpage>1372</fpage>&#x02013;<lpage>1381</lpage>, <pub-id pub-id-type="doi">10.4049/jimmunol.1700187</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="iid370203-cit-0043">
<string-name>
<given-names>K.</given-names>
<surname>Kaarniranta</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Pawlowska</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Szczepanska</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Blasiak</surname>
</string-name>, &#x0201c;<article-title>DICER1 in the Pathogenesis of Age&#x02010;Related Macular Degeneration (AMD)&#x02014;<italic toggle="yes">Alu</italic> RNA Accumulation Versus miRNA Dysregulation</article-title>,&#x0201d; <source>Aging and Disease</source>
<volume>11</volume> (<year>2020</year>): <fpage>851</fpage>&#x02013;<lpage>862</lpage>, <pub-id pub-id-type="doi">10.14336/AD.2019.0809</pub-id>.<pub-id pub-id-type="pmid">32765950</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="iid370203-cit-0044">
<string-name>
<given-names>L.</given-names>
<surname>Celkova</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Doyle</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Campbell</surname>
</string-name>, &#x0201c;<article-title>NLRP3 Inflammasome and Pathobiology in AMD</article-title>,&#x0201d; <source>Journal of Clinical Medicine</source>
<volume>4</volume> (<year>2015</year>): <fpage>172</fpage>&#x02013;<lpage>192</lpage>, <pub-id pub-id-type="doi">10.3390/jcm4010172</pub-id>.<pub-id pub-id-type="pmid">26237026</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="iid370203-cit-0045">
<string-name>
<given-names>Y. S.</given-names>
<surname>Kwon</surname>
</string-name> and <string-name>
<given-names>Z.</given-names>
<surname>Han</surname>
</string-name>, &#x0201c;<article-title>Advanced Nanomedicines for the Treatment of Age&#x02010;Related Macular Degeneration</article-title>,&#x0201d; <source>Nanoscale</source>
<volume>16</volume> (<year>2024</year>): <fpage>16769</fpage>&#x02013;<lpage>16790</lpage>, <pub-id pub-id-type="doi">10.1039/d4nr01917b</pub-id>.<pub-id pub-id-type="pmid">39177654</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="iid370203-cit-0046">
<string-name>
<given-names>N.</given-names>
<surname>Kerur</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Hirano</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Tarallo</surname>
</string-name>, et al., &#x0201c;<article-title>TLR&#x02010;Independent and P2X7&#x02010;Dependent Signaling Mediate Alu RNA&#x02010;Induced NLRP3 Inflammasome Activation in Geographic Atrophy</article-title>,&#x0201d; <source>Investigative Opthalmology &#x00026; Visual Science</source>
<volume>54</volume> (<year>2013</year>): <fpage>7395</fpage>&#x02013;<lpage>7401</lpage>, <pub-id pub-id-type="doi">10.1167/iovs.13-12500</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="iid370203-cit-0047">
<string-name>
<given-names>M.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Qiu</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Wang</surname>
</string-name>, et al., &#x0201c;<article-title>P2X7 Receptor Antagonist Attenuates Retinal Inflammation and Neovascularization Induced by Oxidized Low&#x02010;Density Lipoprotein</article-title>,&#x0201d; <source>Oxidative Medicine and Cellular Longevity</source>
<volume>2021</volume> (<year>2021</year>): <elocation-id>5520644</elocation-id>, <pub-id pub-id-type="doi">10.1155/2021/5520644</pub-id>.<pub-id pub-id-type="pmid">34457115</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="iid370203-cit-0048">
<string-name>
<given-names>P.</given-names>
<surname>Sekar</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Hsiao</surname>
</string-name>, <string-name>
<given-names>Y. S.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>W. W.</given-names>
<surname>Lin</surname>
</string-name>, and <string-name>
<given-names>C. M.</given-names>
<surname>Chan</surname>
</string-name>, &#x0201c;<article-title>P2X7 Is Involved in the Mouse Retinal Degeneration via the Coordinated Actions in Different Retinal Cell Types</article-title>,&#x0201d; <source>Antioxidants</source>
<volume>12</volume> (<year>2023</year>): <elocation-id>141</elocation-id>, <pub-id pub-id-type="doi">10.3390/antiox12010141</pub-id>.<pub-id pub-id-type="pmid">36671003</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="iid370203-cit-0049">
<string-name>
<given-names>K. A.</given-names>
<surname>Vessey</surname>
</string-name>, <string-name>
<given-names>B. J.</given-names>
<surname>Gu</surname>
</string-name>, <string-name>
<given-names>A. I.</given-names>
<surname>Jobling</surname>
</string-name>, et al., &#x0201c;<article-title>Loss of Function of P2X7 Receptor Scavenger Activity in Aging Mice</article-title>,&#x0201d; <source>American Journal of Pathology</source>
<volume>187</volume> (<year>2017</year>): <fpage>1670</fpage>&#x02013;<lpage>1685</lpage>, <pub-id pub-id-type="doi">10.1016/j.ajpath.2017.04.016</pub-id>.<pub-id pub-id-type="pmid">28628761</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="iid370203-cit-0050">
<string-name>
<given-names>C.</given-names>
<surname>Drysdale</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Park</surname>
</string-name>, <string-name>
<given-names>K. A.</given-names>
<surname>Vessey</surname>
</string-name>, et al., &#x0201c;<article-title>P2X7&#x02010;Mediated Alteration of Membrane Fluidity Is Associated With the Late Stages of Age&#x02010;Related Macular Degeneration</article-title>,&#x0201d; <source>Purinergic Signalling</source>
<volume>18</volume> (<year>2022</year>): <fpage>469</fpage>&#x02013;<lpage>479</lpage>, <pub-id pub-id-type="doi">10.1007/s11302-022-09894-y</pub-id>.<pub-id pub-id-type="pmid">36001279</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="iid370203-cit-0051">
<string-name>
<given-names>D.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>S. G.</given-names>
<surname>Elner</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Clark</surname>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Hughes</surname>
</string-name>, <string-name>
<given-names>H. R.</given-names>
<surname>Petty</surname>
</string-name>, and <string-name>
<given-names>V. M.</given-names>
<surname>Elner</surname>
</string-name>, &#x0201c;<article-title>Activation of P2X Receptors Induces Apoptosis in Human Retinal Pigment Epithelium</article-title>,&#x0201d; <source>Investigative Opthalmology &#x00026; Visual Science</source>
<volume>52</volume> (<year>2011</year>): <fpage>1522</fpage>&#x02013;<lpage>1530</lpage>, <pub-id pub-id-type="doi">10.1167/iovs.10-6172</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="iid370203-cit-0052">
<string-name>
<given-names>D.</given-names>
<surname>Yang</surname>
</string-name>, &#x0201c;<article-title>Targeting the P2X7 Receptor in Age&#x02010;Related Macular Degeneration</article-title>,&#x0201d; <source>Vision</source>
<volume>1</volume> (<year>2017</year>): <elocation-id>11</elocation-id>, <pub-id pub-id-type="doi">10.3390/vision1020011</pub-id>.<pub-id pub-id-type="pmid">31740637</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="iid370203-cit-0053">
<string-name>
<given-names>K. A.</given-names>
<surname>Carver</surname>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bowes Rickman</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Yang</surname>
</string-name>, &#x0201c;<article-title>Lack of the P2X<sub>7</sub> Receptor Protects Against AMD&#x02010;Like Defects and Microparticle Accumulation in a Chronic Oxidative Stress&#x02010;Induced Mouse Model of AMD</article-title>,&#x0201d; <source>Biochemical and Biophysical Research Communications</source>
<volume>482</volume> (<year>2017</year>): <fpage>81</fpage>&#x02013;<lpage>86</lpage>, <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.10.140</pub-id>.<pub-id pub-id-type="pmid">27810364</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="iid370203-cit-0054">
<string-name>
<given-names>A.</given-names>
<surname>Wakx</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Dutot</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Massicot</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Mascarelli</surname>
</string-name>, <string-name>
<given-names>G. A.</given-names>
<surname>Limb</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Rat</surname>
</string-name>, &#x0201c;<article-title>Amyloid &#x003b2; Peptide Induces Apoptosis Through P2X7 Cell Death Receptor in Retinal Cells: Modulation by Marine Omega&#x02010;3 Fatty Acid DHA and EPA</article-title>,&#x0201d; <source>Applied Biochemistry and Biotechnology</source>
<volume>178</volume> (<year>2016</year>): <fpage>368</fpage>&#x02013;<lpage>381</lpage>, <pub-id pub-id-type="doi">10.1007/s12010-015-1878-6</pub-id>.<pub-id pub-id-type="pmid">26467741</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="iid370203-cit-0055">
<string-name>
<given-names>E.</given-names>
<surname>Olivier</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Dutot</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Regazzetti</surname>
</string-name>, et al., &#x0201c;<article-title>P2X7&#x02010;Pannexin&#x02010;1 and Amyloid &#x003b2;&#x02010;Induced Oxysterol Input in Human Retinal Cell: Role in Age&#x02010;Related Macular Degeneration?</article-title>,&#x0201d; <source>Biochimie</source>
<volume>127</volume> (<year>2016</year>): <fpage>70</fpage>&#x02013;<lpage>78</lpage>, <pub-id pub-id-type="doi">10.1016/j.biochi.2016.04.014</pub-id>.<pub-id pub-id-type="pmid">27109381</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="iid370203-cit-0056">
<string-name>
<given-names>M.</given-names>
<surname>Rutar</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Valter</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Natoli</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Provis</surname>
</string-name>, &#x0201c;<article-title>Synthesis and Propagation of Complement C3 by Microglia/Monocytes in the Aging Retina</article-title>,&#x0201d; <source>PLoS One</source>
<volume>9</volume> (<year>2014</year>): <elocation-id>e93343</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0093343</pub-id>.<pub-id pub-id-type="pmid">24705166</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="iid370203-cit-0057">
<string-name>
<given-names>W.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Yao</surname>
</string-name>, &#x0201c;<article-title>Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume> (<year>2022</year>): <elocation-id>4883</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms23094883</pub-id>.<pub-id pub-id-type="pmid">35563274</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="iid370203-cit-0058">
<string-name>
<given-names>D.</given-names>
<surname>Garc&#x000ed;a&#x02010;Garc&#x000ed;a</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Vidal&#x02010;Gil</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Parain</surname>
</string-name>, et al., &#x0201c;<article-title>Neuroinflammation as a Cause of Differential M&#x000fc;ller Cell Regenerative Responses to Retinal Injury</article-title>,&#x0201d; <source>Science Advances</source>
<volume>10</volume> (<year>2024</year>): <elocation-id>eadp7916</elocation-id>, <pub-id pub-id-type="doi">10.1126/sciadv.adp7916</pub-id>.<pub-id pub-id-type="pmid">39356769</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="iid370203-cit-0059">
<string-name>
<given-names>L.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Hou</surname>
</string-name>, and <string-name>
<given-names>N.</given-names>
<surname>Yan</surname>
</string-name>, &#x0201c;<article-title>Neuroinflammation in Retinitis Pigmentosa: Therapies Targeting the Innate Immune System</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>13</volume> (<year>2022</year>): <elocation-id>1059947</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2022.1059947</pub-id>.<pub-id pub-id-type="pmid">36389729</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="iid370203-cit-0060">
<string-name>
<given-names>S.</given-names>
<surname>Notomi</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Hisatomi</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kanemaru</surname>
</string-name>, et al., &#x0201c;<article-title>Critical Involvement of Extracellular ATP Acting on P2RX7 Purinergic Receptors in Photoreceptor Cell Death</article-title>,&#x0201d; <source>American Journal of Pathology</source>
<volume>179</volume> (<year>2011</year>): <fpage>2798</fpage>&#x02013;<lpage>2809</lpage>, <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.08.035</pub-id>.<pub-id pub-id-type="pmid">21983632</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="iid370203-cit-0061">
<string-name>
<given-names>E.</given-names>
<surname>Klose</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Kuhrt</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Kohen</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Wiedemann</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Bringmann</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Hollborn</surname>
</string-name>, &#x0201c;<article-title>Hypoxic and Osmotic Expression of Kir2.1 Potassium Channels in Retinal Pigment Epithelial Cells: Contribution to Vascular Endothelial Growth Factor Expression</article-title>,&#x0201d; <source>Experimental Eye Research</source>
<volume>211</volume> (<year>2021</year>): <elocation-id>108741</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.exer.2021.108741</pub-id>.<pub-id pub-id-type="pmid">34425102</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="iid370203-cit-0062">
<string-name>
<given-names>T.</given-names>
<surname>Puthussery</surname>
</string-name> and <string-name>
<given-names>E.</given-names>
<surname>Fletcher</surname>
</string-name>, &#x0201c;<article-title>Extracellular ATP Induces Retinal Photoreceptor Apoptosis Through Activation of Purinoceptors in Rodents</article-title>,&#x0201d; <source>Journal of Comparative Neurology</source>
<volume>513</volume> (<year>2009</year>): <fpage>430</fpage>&#x02013;<lpage>440</lpage>, <pub-id pub-id-type="doi">10.1002/cne.21964</pub-id>.<pub-id pub-id-type="pmid">19180669</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="iid370203-cit-0063">
<string-name>
<given-names>S. M.</given-names>
<surname>Silverman</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhao</surname>
</string-name>, and <string-name>
<given-names>W. T.</given-names>
<surname>Wong</surname>
</string-name>, &#x0201c;<article-title>C3&#x02010; and CR3&#x02010;Dependent Microglial Clearance Protects Photoreceptors in Retinitis Pigmentosa</article-title>,&#x0201d; <source>Journal of Experimental Medicine</source>
<volume>216</volume> (<year>2019</year>): <fpage>1925</fpage>&#x02013;<lpage>1943</lpage>, <pub-id pub-id-type="doi">10.1084/jem.20190009</pub-id>.<pub-id pub-id-type="pmid">31209071</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="iid370203-cit-0064">
<string-name>
<given-names>F.</given-names>
<surname>Di Virgilio</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Dal Ben</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Sarti</surname>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Giuliani</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Falzoni</surname>
</string-name>, &#x0201c;<article-title>The P2X7 Receptor in Infection and Inflammation</article-title>,&#x0201d; <source>Immunity</source>
<volume>47</volume> (<year>2017</year>): <fpage>15</fpage>&#x02013;<lpage>31</lpage>, <pub-id pub-id-type="doi">10.1016/j.immuni.2017.06.020</pub-id>.<pub-id pub-id-type="pmid">28723547</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="iid370203-cit-0065">
<string-name>
<given-names>H. G.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Won</surname>
</string-name>, <string-name>
<given-names>B. J.</given-names>
<surname>Gwag</surname>
</string-name>, and <string-name>
<given-names>Y. B.</given-names>
<surname>Lee</surname>
</string-name>, &#x0201c;<article-title>Microglial P2X<sub>7</sub> Receptor Expression is Accompanied by Neuronal Damage in the Cerebral Cortex of the APP<sub>swe</sub>/PS1dE9 Mouse Model of Alzheimer's Disease</article-title>,&#x0201d; <source>Experimental and Molecular Medicine</source>
<volume>43</volume> (<year>2011</year>): <fpage>7</fpage>, <pub-id pub-id-type="doi">10.3858/emm.2011.43.1.001</pub-id>.<pub-id pub-id-type="pmid">21088470</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="iid370203-cit-0066">
<string-name>
<given-names>C. E.</given-names>
<surname>Gallenga</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lonardi</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Pacetti</surname>
</string-name>, et al., &#x0201c;<article-title>Molecular Mechanisms Related to Oxidative Stress in Retinitis Pigmentosa</article-title>,&#x0201d; <source>Antioxidants</source>
<volume>10</volume> (<year>2021</year>): <elocation-id>848</elocation-id>, <pub-id pub-id-type="doi">10.3390/antiox10060848</pub-id>.<pub-id pub-id-type="pmid">34073310</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="iid370203-cit-0067">
<string-name>
<given-names>L. D.</given-names>
<surname>Church</surname>
</string-name>, <string-name>
<given-names>G. P.</given-names>
<surname>Cook</surname>
</string-name>, and <string-name>
<given-names>M. F.</given-names>
<surname>McDermott</surname>
</string-name>, &#x0201c;<article-title>Primer: Inflammasomes and Interleukin 1&#x003b2; in Inflammatory Disorders</article-title>,&#x0201d; <source>Nature Clinical Practice. Rheumatology</source>
<volume>4</volume> (<year>2008</year>): <fpage>34</fpage>&#x02013;<lpage>42</lpage>, <pub-id pub-id-type="doi">10.1038/ncprheum0681</pub-id>.</mixed-citation></ref><ref id="iid370203-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="iid370203-cit-0068">
<string-name>
<given-names>B. J.</given-names>
<surname>Gu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Field</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Dutertre</surname>
</string-name>, et al., &#x0201c;<article-title>A Rare P2X7 Variant Arg307Gln With Absent Pore Formation Function Protects Against Neuroinflammation in Multiple Sclerosis</article-title>,&#x0201d; <source>Human Molecular Genetics</source>
<volume>24</volume> (<year>2015</year>): <fpage>5644</fpage>&#x02013;<lpage>5654</lpage>, <pub-id pub-id-type="doi">10.1093/hmg/ddv278</pub-id>.<pub-id pub-id-type="pmid">26188005</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="iid370203-cit-0069">
<string-name>
<given-names>B. J.</given-names>
<surname>Gu</surname>
</string-name>, <string-name>
<given-names>P. N.</given-names>
<surname>Baird</surname>
</string-name>, <string-name>
<given-names>K. A.</given-names>
<surname>Vessey</surname>
</string-name>, et al., &#x0201c;<article-title>A Rare Functional Haplotype of the P2RX4 and P2RX7 Genes Leads to Loss of Innate Phagocytosis and Confers Increased Risk of Age&#x02010;Related Macular Degeneration</article-title>,&#x0201d; <source>FASEB Journal</source>
<volume>27</volume> (<year>2013</year>): <fpage>1479</fpage>&#x02013;<lpage>1487</lpage>, <pub-id pub-id-type="doi">10.1096/fj.12-215368</pub-id>.<pub-id pub-id-type="pmid">23303206</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="iid370203-cit-0070">
<string-name>
<given-names>C. B. M.</given-names>
<surname>Platania</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Giurdanella</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Di Paola</surname>
</string-name>, et al., &#x0201c;<article-title>P2X7 Receptor Antagonism: Implications in Diabetic Retinopathy</article-title>,&#x0201d; <source>Biochemical Pharmacology</source>
<volume>138</volume> (<year>2017</year>): <fpage>130</fpage>&#x02013;<lpage>139</lpage>, <pub-id pub-id-type="doi">10.1016/j.bcp.2017.05.001</pub-id>.<pub-id pub-id-type="pmid">28479300</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="iid370203-cit-0071">
<string-name>
<given-names>C. B. M.</given-names>
<surname>Platania</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Lazzara</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fidilio</surname>
</string-name>, et al., &#x0201c;<article-title>Blood&#x02010;Retinal Barrier Protection Against High Glucose Damage: The Role of P2X7 Receptor</article-title>,&#x0201d; <source>Biochemical Pharmacology</source>
<volume>168</volume> (<year>2019</year>): <fpage>249</fpage>&#x02013;<lpage>258</lpage>, <pub-id pub-id-type="doi">10.1016/j.bcp.2019.07.010</pub-id>.<pub-id pub-id-type="pmid">31302133</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="iid370203-cit-0072">
<string-name>
<given-names>S.</given-names>
<surname>Pavlou</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Augustine</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Cunning</surname>
</string-name>, et al., &#x0201c;<article-title>Attenuating Diabetic Vascular and Neuronal Defects by Targeting P2rx7</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>20</volume> (<year>2019</year>): <elocation-id>2101</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms20092101</pub-id>.<pub-id pub-id-type="pmid">31035433</pub-id>
</mixed-citation></ref><ref id="iid370203-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="iid370203-cit-0073">
<string-name>
<given-names>N.</given-names>
<surname>Piippo</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Korhonen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hytti</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kinnunen</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kaarniranta</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Kauppinen</surname>
</string-name>, &#x0201c;<article-title>Oxidative Stress Is the Principal Contributor to Inflammasome Activation in Retinal Pigment Epithelium Cells With Defunct Proteasomes and Autophagy</article-title>,&#x0201d; <source>Cellular Physiology and Biochemistry</source>
<volume>49</volume> (<year>2018</year>): <fpage>359</fpage>&#x02013;<lpage>367</lpage>, <pub-id pub-id-type="doi">10.1159/000492886</pub-id>.<pub-id pub-id-type="pmid">30138927</pub-id>
</mixed-citation></ref></ref-list></back></article>